Targeting Patients’ Needs With Device Centric Therapy for Symptomatic and Anti-Inflammatory Treatments

Günter Nadler, Director of Business Development for Allergic Rhinitis and and Cough & Cold Solutions at Aptar Pharma, will trace more than five decades of innovation in topical nasal spray development. From the first registered nasal spray products in the 1970s and 1980s to today’s advanced laterally actuated systems, Aptar Pharma has continuously helped shape the market and raise the standard for patient-centered nasal delivery. The presentation will highlight landmark innovations including preservative-free multidose technologies, the expansion of pressurized continuous spray applications with Bag-on-Valve into nasal saline, and the development of adjustable spray solutions, combining a gentle spray and rinsing jet in one device. Going a step beyond conventional nasal spray application, an innovative way of targeting upper airways was defined with the development of PureHale® technology. He will also elaborate on how our expertise extends beyond device technology and how Aptar Pharma´s capabilities support customers journeys from formulation to patient, demonstrating a long-standing leadership at the spearhead of nasal spray innovation within the industry.